Skip to main content
. Author manuscript; available in PMC: 2019 Apr 10.
Published in final edited form as: Cancer Lett. 2018 Apr 10;419:210–221. doi: 10.1016/j.canlet.2018.01.050

Fig. 1. Cancer chemotherapy: Immune effects of low-dose, medium-dose, high-dose options.

Fig. 1

Cancer chemotherapeutic drugs may be non-immunogenic (yellow rectangles) or immunogenic; the latter may be further divided into three categories based on the dose and schedule: Low-dose daily metronomic chemotherapy (blue), medium-dose and intermediate-length intermittent chemotherapy schedule (MEDIC, a modified form of metronomic chemotherapy, red), and high-dose with long drug-free break schedule (MTD, green). The impact of each treatment regimen on tumor cell killing and immune responses is shown.